We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rituximab selectively suppresses specific islet antibodies.
- Authors
Yu, Liping; Herold, Kevan; Krause-Steinrauf, Heidi; McGee, Paula L; Bundy, Brian; Pugliese, Alberto; Krischer, Jeff; Eisenbarth, George S; Type 1 Diabetes TrialNet Anti-CD20 Study Group
- Abstract
The TrialNet Study Group evaluated rituximab, a B-cell-depleting monoclonal antibody, for its effect in new-onset patients with type 1A diabetes. Rituximab decreased the loss of C-peptide over the first year of follow-up and markedly depleted B lymphocytes for 6 months after administration. This article analyzes the specific effect of rituximab on multiple islet autoantibodies.
- Publication
Diabetes, 2011, Vol 60, Issue 10, p2560
- ISSN
1939-327X
- Publication type
Journal Article
- DOI
10.2337/db11-0674